Sibutramine offers three types of benefit in weight management: by enhancing weight loss, by improving weight maintenance and by reducing the comorbidities of obesity. The clinical effects of sibutramine are explained through its known mode of action as a serotonin (5-HT) and noradrenaline reuptake inhibitor (SNRI). This dual mechanism of action results in two synergistic physiological effects -a reduction in energy intake and an increase in energy expenditure, which combine to promote and maintain weight loss. International Journal of Obesity (2001) 25, Suppl 4, S8 -S11.
Introduction
Sibutramine is a novel compound which establishes a new class of drug for weight management. When administered daily as part of a weight management programme that includes diet and exercise, sibutramine allows patients to lose weight and to maintain energy balance at a lower body weight.
The weight loss induced by sibutramine is achieved by two complementary physiological effects.
Enhanced satiety
First, sibutramine promotes satiety after eating. This leads to a reduced food intake and decreased tendency towards snacking. It is important to note that sibutramine does not induce, as a primary effect, a state of anorexia which can be unpleasant. Instead, it enhances and may extend satiety by inducing a feeling of fullness after eating. Studies in which patients have been asked to rate their feelings of satiety on a visual analogue scale (VAS) have shown that sibutraminetreated subjects achieve higher scores than untreated subjects. 1 Eighteen clinical studies conducted with sibutramine assessed satiety using VAS and, despite these studies not being powered to detect secondary end-points, data from nine of the 18 studies show a significant effect of sibutramine on satiety, food cravings, hunger and snacking. For example, a 1 y, family practitioner study reported that daily sibutramine treatment was associated with significant enhancement of satiety (P < 0.01), a reduction in hunger scores (P < 0.001), and reduced cravings for sweet foodstuffs (P < 0.05) and for carbohydrates (P < 0.01).
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A study by Chapelot et al designed to assess energy intake over a 24 h period found that sibutramine treatment could significantly (P < 0.001) reduce total daily energy intake by about 1.3 MJ (310 kcal=day). 3 From such evaluations of reduced energy intake, it is possible to predict the potential effect of sibutramine on weight over time. Assuming a continued total energy deficit per day of 1.3 MJ or 310 calories, it can be calculated that, over a 3-month period, a deficit of some 27 900 kcal will occur, approximating to around 4 kg of weight loss. More importantly, if this deficit is maintained and assuming no compensatory reduction in energy expenditure, the calculation can be extrapolated further to predict that reduced energy intake would achieve energy balance with the mainenance of 13 kg weight loss.
Energy expenditure stimulated
Energy intake to maintain a given body weight comprises three major drivers -the basal metabolic rate, thermogenesis in response to food and the thermogenic consequences of supporting physical activity. The cost of movement and activity is increased in obese subjects, thermogenesis may be reduced, and basal rate is known to increase with a rise in body fat and the associated rise in lean body mass.
It is also known that during and following weight gain, there is an increase in total daily energy requirement, and that conversely, with weight loss, there is normally a decline in metabolic rate. The second effect of sibutramine is to stimulate energy expenditure, so limiting the decline in metabolic rate that normally accompanies weight loss. This action, mediated in experimental animals by brown adipose tissue thermogenesis, is well described. The relative effect is smaller in humans but can be estimated as a relative increase of around 100 kcal per day. 4, 5 Whether the thermogenic effect of sibutramine is mediated by brown adipose tissue in humans is unproven. In human adults, brown adipose tissue (all the internal, non-subcutaneous fat) is usually inactive and greatly expanded by lipid accumulation. However, its metabolic capacity for the thermogenesis remains, and can be stimulated by catecholamines, eg with a phaochromocytoma.
These dual actions of sibutramine to restrain food intake and to limit the decline in metabolic rate post-weight loss combine to ensure that the weight loss achieved by this treatment is greater than that which would be possible through reduced energy intake alone.
Dual pharmacological action
The pharmacological effect of sibutramine is also two-fold. Sibutramine is a centrally acting, monoamine reuptake inhibitor, blocking the reuptake of both serotonin (5-HT) and noradrenaline. This unique mechanism of action distinguishes sibutramine from other centrally acting agents that are known to promote weight loss (see Table 1 ).
Unlike drugs such as dexfenfluramine, which cause release of the neurotransmitter 5-HT and its subsequent depletion, 6 sibutramine is devoid of neurotransmitterreleasing activity. 7 It is this lack of transmitter-releasing activity that is believed to distinguish sibutramine, which effects its action through reuptake inhibition, from all previous or current weight-loss agents. This is particularly so for the amphetamines, including phentermine, which operate principally by stimulating noradrenaline and dopamine release, 8 a feature which physiologically promotes anorexia. Sibutramine has the effect of a reuptake inhibitor in augmenting the stimuli to satiety in the hypothalamus, rather than creating new signals by causing transmitter release.
Enhanced actions on noradrenaline and=or 5-HT systems such as those displayed by sibutramine leads to an earlier onset of satiety after meals. Finally, sibutramine does not inhibit monoamine oxidase, 9 thus avoiding the side effects associated with this mode of action.
Sibutramine decreases food intake by enhancing central noradrenaline and 5-HT function -the synergistic effects of these neurotransmitters are mediated through a 1 and b 1 adrenoceptors and 5-HT 2A=2C receptors. The attenuation in the decline in energy expenditure post-weight loss also involves the combined interaction between enhanced noradrenaline and increased 5-HT function in the central nervous system (CNS). This results in the selective activation of sympathetic drive to a variety of tissues. In rodents, this includes brown adipose tissue via indirect activation of b 3 adrenoceptors.
Improved pharmacological profile
The amphetamines, which also induce weight loss, are associated with addiction and alteration of mood -properties thought to be particularly associated with the transmitter-releasing actions of these drugs on dopaminergic pathways. Sibutramine's distinct mechanism of action to reduce the reuptake of noradrenaline and 5-HT from central neurones, but without significantly influencing the dopamine system, supports the wealth of extensive preclinical, clinical and post-marketing data to demonstrate that sibutramine has a low potential for abuse. 10, 11 In the study by Cole et al, 10 which was designed to evaluate the potential abuse liability of sibutramine compared with dexamphetamine and placebo in recreational stimulant users, the response to the 'street value' questions also indicated a lack of abuse potential for sibutramine (see Figure 1) . 
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Mean dollar estimates of 'street value' for dexamphetamine were significantly greater than placebo (P < 0.05). Estimates for sibutramine 20 and 30 mg did not separate from placebo, but were significantly different (P < 0.05) from both dose levels of dextroamphetamine. The percentages of patients by treatment for the most enjoyed session were: dextroamphetamine 30 mg: 45%; dextroamphetamine 20 mg: 28%; placebo: 14%; sibutramine 30 mg: 7%; sibutramine 20 mg: 0%. The use of fenfluramines is associated with the rare but important risk of primary pulmonary hypertension and uncontrolled case reports suggested possible heart valve incompetence. 12 Post-marketing surveillance data based on over 3.7 million patient-exposures to sibutramine have not been associated with cardiac valvulopathy or PPH. Similarly, data from clinical trials have shown no evidence of either PPH, cardiac valve dysfunction 13 or an increased incidence of dyspnoea. Interestingly, echocardiographic studies indicate that subclinical valve incompetence is relatively common in obese subjects irrespective of whether or not they have had drug therapy.
Sibutramine -effects on cardiovascular risk factors
The physiological effects of sibutramine include stimulation of the sympathetic nervous system so pulse rates and blood pressure increases are to be expected. Weight loss serves to minimise or even reverse these effects -especially the effect on blood pressure -and sibutramine-treated patients have a fall in blood pressure proportional to their weight loss, albeit not as low as that seen in the smaller number of patients who manage to achieve the same weight loss by diet alone. The sibutramine-assisted weight loss itself then reduces the risk of other obesity-related comorbidities, such as abnormal lipids and type 2 diabetes, to the same degree as expected from the amount of weight loss.
A number of studies have shown that sibutramine treatment has beneficial effects on secondary efficacy variables such as lipid profile and glycaemic control. Sibutramineinduced weight loss may help to improve long-term control of diabetes and papers within this supplement (see Van Gaal and Peiffer, and Sharma, in this issue) consider in more detail the role of sibutramine in the management of obesity in these obese=overweight patients with type 2 diabetes and also in obese=overweight patients with hypertension, respectively.
Weight loss and weight maintenance
As shown in Figure 2 , successful weight management is considered to include not only initial weight loss over a matter of months, but also maintenance of weight at a lower level over a period of years.
The pharmacological actions of sibutramine result in augmented weight loss, which is usually complete within 6 months. Daily treatment with sibutramine then leads to a better maintenance of weight over at least a 24-month period than would be obtained when using diet and lifestyle changes alone, or by use of drugs such as fluoxetine which act on a single monoamine system. 14 The results of the STORM study which looked at mean body weight changes during the weight-loss period and over a weight maintenance phase totalling 2 y, showed that, compared with patients managed by diet and exercise alone, some 43% of obese patients given daily sibutramine, in addition to the same diet and exercise, maintained 80% or more of their weight loss (see Figure 3 ). Only 16% of control patients (previously treated with sibutramine) managed to achieve this level of sustained weight loss. Thus sibutramine treatment had a significant (P < 0.001) effect on weight maintenance as compared with diet and exercise alone. The amount of weight loss maintained on sibutramine is about 12 kg below the expected weight with no intervention, 15 similar to that predicted from its effect on food consumption. 
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Summary
Sibutramine offers three types of benefit in weight management: by enhancing weight loss, improving weight maintenance; and by reducing the comorbidities of obesity. The clinical effects of sibutramine are explained through its known mode of action. Sibutramine induces initial weight loss and continues to be effective long-term, once the expected plateau in weight loss has occurred. The longterm impact of sibutramine should be compared with the expected weight gain of 1 -2 kg per year in the obesity-prone population. 15 
